Davita Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Davita Inc 's ROA in the second quarter of 2026?
Davita Inc achieved a return on average assets (ROA) of 6.75 % in its second quarter of 2026, this is above DVA's average return on assets of 5.12%.
Davita Inc s assets during the 12 months ending in the second quarter of 2026 are valued at $17 billion

ROA has improved compared to 6.38% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 133 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 973, from total ROA ranking in the first quarter of 2026 at 1160.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	0.98 %	3.2 %	18.42 %	16.36 %	20.06 %
Y / Y Net Income Change	24.71 %	18.44 %	-5.22 %	-18.77 %	-8.18 %
Net Income (TTM) in million	1,190	1,122	1,079	1,097	1,152
Return On Assets (TTM)	6.75 %	6.38 %	6.18 %	6.54 %	7.14 %
DVA's Total Ranking	# 973	# 1160	# 980	# 939	# 919
Total Assets (TTM) in million	17,665	17,667	17,637	17,556	17,493
Seq. Total Assets Change	-0.01 %	0.17 %	0.46 %	0.36 %	2.18 %
Seq. Net Income Change	24.79 %	-16.92 %	37.79 %	-12.71 %	18.52 %

DVA's 5 Years Annual ROA >> Back to DVA Management Effectiveness >> Compare DVA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 16
Sector	# 134
Overall	# 920

Return On Assets Statistics
High	Average	Low
9.48 %	5.12 %	1.48 %
(March 31, 2007)		(Mar 31 2019)

Financial Statements
Davita Inc 's Assets	$ 17,665 million	DVA's Balance sheet
Davita Inc 's Income	$ 343 million	Quarterly DVA's Income Statement
DVA's Income by Division		See DVA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	18.42 %	3.47 %	0.92 %	-0.25 %	1.22 %
Total Assets in million	17,637	14,894	14,395	14,264	14,301
Y / Y Net Income Change	-13.75 %	30.7 %	22.43 %	-35.5 %	21.82 %
Net Income in million	1,079	1,251	957	782	1,212
Annual Return On Assets	6.12 %	8.4 %	6.65 %	5.48 %	8.47 %

DVA's 5 Years Annual ROA >> Back to DVA Management Effectiveness >> Compare DVA ROA to its Competitors

Comment on DVA's ROA in the fiscal year ending 2025

In the fiscal year 2025 Davita Inc 's ROA decreased compared to previous year to 6.12 %, due to deterioration of net income -13.75 % to $1,078.72 million, from $1,250.74 million a year ago, as DVA's assets were $17,637.35 million.

More Return On Assets Ratios
DVA's' Return on Assets at Yahoo Finance
Healthcare Facilities Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DVA's Roa Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DVA's Competitors
Subscribers only: Roa for Davita Inc 's Suppliers
Subscribers only: Return On Assets for DVA's Customers

You may also want to know
DVA's Roi	DVA's Inventory Turnover Ratio	DVA's Growth Rates	DVA's Dividend Comparisons
	DVA's Profitability Ratios	DVA's Asset Turnover Ratio	DVA's Dividend Growth
DVA's Roe	DVA's Valuation Ratios	DVA's Financial Strength Ratios	DVA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %
Sbc Medical Group Holdings Incorporated	13.26 %
Alpha Pro Tech Ltd	13.17 %
Illumina Inc	12.68 %
Spero Therapeutics Inc	12.57 %
Transmedics Group Inc	12.50 %
Eton Pharmaceuticals Inc	12.37 %
Nephros Inc	12.30 %
Msa Safety Inc	12.23 %

Date modified: 2026-09-12T06:12:50+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.